Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an <i>in vitro</i> investigation

Xiang, Dong; Wang, Chenguang; Wang, Wen Qing; Shi, Chun Yang; Xiong, Wei; Wang, Meng Die; Fang, Jim

doi:10.1080/09637486.2016.1276518

Cited by 75 publications

(49 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher solubility was observed in both cocrystals and an approximately 5-fold enhancement in bioavailability of DMY was achieved after oral administration in rats (Wang & Tong., 2016). Moreover, the formation of phytosomes, liposomes, microcapsules, and molecular structure modification would be good alternative to improving the bioavailability of DMY (Xiang, Wang, & Wang, 2017).…”

Section: Discussionmentioning

confidence: 99%

Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco‐2 Cells

Fan

Hou

Xiong

et al. 2018

Journal of Food Science

Self Cite

View full text Add to dashboard Cite

This study elucidated the uptake and transport characteristics of dihydromyricetin (DMY). DMY was poorly absorbed by a passive diffusion mechanism. The uptake and transport of DMY were time and concentration dependent. Interestingly, pH affected DMY uptake but not its bidirectional transport. MRP2 and BCRP were involved in the uptake and transport of DMY, which hindered the absorption of DMY in the intestinal. Thus, the present study may provide useful information for designing DMY delivery systems and avoiding DMY-drug interactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco‐2 Cells

Fan

Hou

Xiong

et al. 2018

Journal of Food Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…The phenol hydroxyl structure of DMY makes it unstable and undergoes many chemical changes such as oxidation, hydrolysis, ring fission and reduction, which resulted in metabolite formations (Xiang et al, 2017). Chemical stability of DMY is influenced by pH buffer, temperature, as well as the presence of metal ions such as Fe 3+ , Al 3+ , Cu 2+ .…”

Section: Chemical Stabilitymentioning

confidence: 99%

Dihydromyricetin: A review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability

Liú

Mao

Ding

et al. 2019

Trends in Food Science & Technology

107

View full text Add to dashboard Cite

Background: Dihydromyricetin (DMY) is an important plant flavonoid, which has received great attention due to its health-benefiting activities, including antioxidant, antimicrobial, anti-inflammatory, anticancer, antidiabetic and neuroprotective activities. DMY capsules have been sold in US as a nutraceutical supplement to prevent alcoholic hangovers. The major disadvantage associated with DMY is its chemical instability and poor bioavailability caused by the combined effects of its low solubility and poor membrane permeability. This limits its practical use in the food and pharmaceutical fields. Scope and approach: The present paper gives an overview of the current methods for the identification and quantification of DMY. Furthermore, recent findings regarding the main biological properties and chemical stability of DMY, the metabolism of DMY as well as different approaches to increase DMY bioavailability in both aqueous and lipid phases are discussed. Key findings and conclusions: Current trends on identification and quantification of DMY have been focused on spectral and chromatographic techniques. Many factors such as heat, pH, metal ions, could affect the chemical stability of DMY. Despite the diverse biological effects of DMY, DMY faces with the problem of poor bioavailability. Utilization of different delivery systems including solid dispersion, nanocapsule, microemuslion, cyclodextrin inclusion complexes, co-crystallization, phospholipid complexes, and chemical or enzymatic acylation has the potential to improve both the solubility and bioavailability. DMY digested in laboratory animals undergoes reduction, dehydroxylation, methylation, glucuronidation, and sulfation. Novel DMY delivery systems and basic pharmacokinetic studies of encapsulated DMY on higher animals and humans might be required in the future.

show abstract

“…However, the effects of MYR on hepatic glucose and lipid regulation in animal models of type 2 diabetes are not fully understood to date. Although its aglycone myricetin has been suggested to have potential for the treatment of type 2 diabetes [9][10][11], direct absorption of the glycosylated form and a higher gastrointestinal stability of MYR than myricetin were reported [12][13][14]. Therefore, it is required to evaluate the effects of MYR on type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

Myricitrin Ameliorates Hyperglycemia, Glucose Intolerance, Hepatic Steatosis, and Inflammation in High-Fat Diet/Streptozotocin-Induced Diabetic Mice

Kim

Jung

2020

IJMS

View full text Add to dashboard Cite

To test the hypothesis that myricitrin (MYR) improves type 2 diabetes, we examined the effect of MYR on hyperglycemia, glucose intolerance, hepatic steatosis, and inflammation in high-fat diet (HFD) and streptozotocin (STZ)-induced type 2 diabetic mice. Male C57BL/6J mice were randomly divided into three groups: non-diabetic, diabetic control, and MYR (0.005%, w/w)-supplemented diabetic groups. Diabetes was induced by HFD and STZ, and MYR was administered orally for 5 weeks. Myricitrin exerted no significant effects on food intake, body weight, fat weight, or plasma lipids levels. However, MYR significantly decreased fasting blood glucose levels, improved glucose intolerance, and increased pancreatic β-cell mass compared to the diabetic control group. Myricitrin administration also markedly increased glucokinase mRNA expression and activity as well as lowered glucose-6-phosphatase and phosphoenolpyruvate carboxykinase mRNA expression and activity in the liver. In addition, liver weight, hepatic triglyceride content, and lipid droplet accumulation were markedly decreased following MYR administration. These changes were seemingly attributable to the suppression of the hepatic lipogenic enzymes—fatty acid synthase and phosphatidate phosphohydrolase. Myricitrin also significantly lowered plasma MCP-1 and TNF-α levels and the mRNA expression of hepatic pro-inflammatory genes. These results suggest that MYR has anti-diabetic potential.

show abstract

Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an in vitro investigation

Cited by 75 publications

References 28 publications

Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco‐2 Cells

Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco‐2 Cells

Dihydromyricetin: A review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability

Myricitrin Ameliorates Hyperglycemia, Glucose Intolerance, Hepatic Steatosis, and Inflammation in High-Fat Diet/Streptozotocin-Induced Diabetic Mice

Contact Info

Product

Resources

About